Rémi Palmantier has joined French biotechnology firm Genticel as Chief Scientific Officer.
A seasoned scientist with broad international experience, Palmantier joins the clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), from GSK Vaccines, where he was most recently Senior Director, R&D, for the global portfolio of immunotherapies for chronic diseases.
Prior to this, Palmantier was Head of Cancer Preclinical Immunotherapies at GSK Biologicals (Canada), and was involved in evaluating external opportunities for licensing to build a portfolio of immunotherapeutic candidates. He started his career with GSK Biologicals in 1997 and held various scientific positions in the Therapeutic Cancer Vaccine Programme.
Palmantier's expertise will facilitate the discovery, development and integration of specific immunotherapies at Genticel. His track record of successfully developing drug candidates will support the Company's strategy to expand its pipeline of innovative immunotherapies and to target various types of infectious diseases and cancers, beyond its advanced program of HPV therapeutic vaccines.
Marie-Christine Bissery, a member of Genticel's Management Board and previous Chief Scientific Officer, is appointed Chief Development Officer and is responsible for overseeing all project management activities in the company.
